UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
LIQUIDIA TECHNOLOGIES, Inc., Petitioner,
V.
UNITED THERAPEUTICS CORPORATION, Patent Owner.
IPR2021-00406 U.S. Patent No. 10,716,793

PATENT OWNER UPDATED EXHIBIT LIST



EXHIBIT LIST

Exhibit	Description
EX2001	Declaration of Dr. Aaron Waxman
EX2002	Dr. Waxman's curriculum vitae
EX2003	Declaration of Dr. Werner Seeger
EX2004	Declaration of Dr. Hossein A. Ghofrani
EX2005	Declaration of Dr. Frank Reichenberger
EX2006	Declaration of Dr. Friedrich Grimminger
EX2007	Tyvaso Orange Book listing
EX2008	Hill, N., 2005, Therapeutic Options for the Treatment of
	Pulmonary Hypertension, Medscape Pulmonary Medicine 9(2).
EX2009	Substantive Submission filed in 12/591,200 (Mar. 9, 2015)
EX2010	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-1 (public
	docket)
EX2011	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-11 (public
	docket)
EX2012	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-16 (public
	docket)
EX2013	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), unnumbered
	docket entry dated 7/30/2020
EX2014	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-20 (public
	docket) (excerpted)
EX2015	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-29 (public
EN/2016	docket)
EX2016	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-45 (public
	docket)



Exhibit	Description
EX2017	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-21 (public
	docket)
EX2018	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-41 (public
	docket)
EX2019	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-49 (public
	docket)
EX2020	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-68 (public
	docket)
EX2021	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-71 (public
	docket)
EX2022	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-40 (public
	docket)
EX2023	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-47 (public
	docket)
EX2024	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-75 (public
	docket)
EX2025	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-80 (public
	docket)
EX2026	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-81 (public
	docket)
EX2027	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-92 (public
	docket)



Exhibit	Description
EX2028	United Therapeutics Corporation v. Liquidia Technologies, Inc.,
	Case No. 1:20-cv-00755-RGA-JLH (D. Del.), ECF-74 (public
	docket)
EX2029	Hess et al., 2007, A guide to aerosol delivery devices for
	respiratory therapists. American Association for Respiratory
	Care
EX2030	Dennis JH, 2002, Standardization issues: in vitro assessment of
	nebulizer performance. Respir. Care. 47(12):1455-1458
EX2031	Hess et al., 1996, Medication nebulizer performance. Effects of
	diluent volume, nebulizer flow, and nebulizer brand. Chest,
	110(2):498-505
EX2032	Rubin BK et al., 2008 Treatment Delivery Systems (in Clinical
	Asthma), available at
	https://www.sciencedirect.com/topics/medicine-anddentistry/
	nebulizer
EX2033	Gardenhire, D.S. et al., 2017, A Guide to Aerosol Delivery
	Devices for Respiratory Therapists (4th Ed.) American
	Association for Respiratory Care
EX2034	Tyvaso® Label 2021
EX2035	Bourge et al., Cardiovascular Therapeutics, 31:38-44 (2013)
EX2036	McLaughlin et al., Efficacy and safety of treprostinil: an
	epoprostenol analog for primary pulmonary hypertension, J.
	Cardiovascular Pharmacology, 41:293-299 (2003)
EX2037	Springer website (from fn 13 of Hall-Ellis Decl)
EX2038	(Intentionally Left Blank)
EX2039	Springer website (from fn 14 of Hall-Ellis Decl)
EX2040	University of Wisconsin-Madison Library Catalog Search for
	holdings of Circulation: the journal of the American Heart
	Association
EX2041	Declaration of Ms. Pilar Wyman
EX2042	Ms. Pilar Wyman's curriculum vitae
EX2043	Deposition Transcript of Sylvia Hall-Ellis, Ph. D.



Exhibit	Description
EX2044	American Heart Association Listing of Circulation Supplements
EX2045	Chemical Abstracts Plus Search Results Transcript
EX2046	Ovid Search Results for "Voswinckel"
EX2047	PubMed Search Results for "Voswinckel"
EX2048	Compilation Showing Search Results for Descriptor Terms
EX2049	Oxford Academic Listing of European Heart Journal
	Supplements
EX2050	Simonneau et al., Updated Clinical Classification of Pulmonary
	Hypertension., J Am. College of Cardiol, 62(25)D34-D42 at
	D34-D35 (2013)
EX2051	Sitbon and Noordegraaf, Epoprostenol and pulmonary arterial
	hypertension: 20 years of clinical experience, Eur. Respir Rev.
	26:160055 (2017)
EX2052	Second Declaration of Dr. Aaron Waxman
EX2053	Declaration of Dr. Jason McConville
EX2054	Dr. McConville's curriculum vitae
EX2055	Deposition of Dr. Nicholas Hill (Oct. 17, 2021), IPR2021-00406
EX2056	Deposition of Igor Gonda, Ph. D. (Oct. 26, 2021), IPR2021-
	00406
EX2057	Vital Signs (Body Temperature, Pulse Rate, Respiration Rate,
	Blood Pressure), Johns Hopkins Medicine, available at
	https://www.hopkinsmedicine.org/health/conditions-and-
	diseases/vital-signs-body-temperature-pulse-rate-respiration-
	rate-blood-pressure
EX2058	Pharmacokinetics of Inhaled Drugs, available at
	https://media.lanecc.edu/users/driscolln/RT127/Softchalk/
	Pharmcology_SFTCHLK_Lesson/Pharmacology_lesson10.html
EX2059	(Intentionally Left Blank)
EX2060	Waxman et al., Inhaled Treprostinil in Pulmonary Hypertension
	Due to Interstitial Lung Disease, N. Eng. J. Med. 384:325-334
	(2021)



DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

